What specific diseases are included in the indications for Niraparib Abiraterone Tablets?

Akeega is an oral combination preparation containing two active ingredients: niraparib and abiraterone acetate. The combination drug is a targeted therapy specifically designed to treat certain types of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC) associated with BRCA gene mutations. Its mechanism of action integrates niraparib's ability to inhibit DNA damage repair and abiraterone's potent inhibition of androgen production, forming a dual-pathway strategy to synergistically attack prostate cancer cells.

According to the current international drug approval standards,Akeega is mainly suitable for male patients who have previously received androgen deprivation therapy (ADT) and are resistant to it, and whose tumor tissue or liquid biopsy has gene mutations in the HRR (homologous recombination repair) pathway, especially BRCA1 or BRCA2 mutations. BRCA mutations are often associated with aggressive prostate cancer and poor prognosis, so Akeega provides highly personalized and precise treatment options. The combined use of the drug also avoids problems such as dosage inconsistency and poor compliance that may occur when using two separate drugs.

In addition,Akeega is often used in combination with glucocorticoids (such as prednisone) to reduce the increase in aldosterone caused by abiraterone and enhance the overall therapeutic effect. With the popularization of prostate cancer molecular typing and genetic testing technology, Akeega's user population is expected to continue to expand. It is not only limited to patients who are ineffective with traditional chemotherapy, but may also exert greater potential in earlier or combined treatment options.

In general, niraparib and abiraterone tablets, as a precision drug for BRCA mutation-positive patients inmCRPC, provide a new direction for the treatment of metastatic prostate cancer, and have been included in personalized treatment recommendations in many countries around the world, and have high clinical value and application prospects.

Reference materials:https://www.drugs.com/akeega.html